Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Kevin McKenzie who wrote (43182)	1/14/1999 11:18:00 AM
From: songw	Read Replies (1) \| Respond to of 119973

CYTL AIDS vaccine sympathy = HIV-formerly CelSci trading 2 CYTL rocketing + 300 % trading 8s on word that its HIV vaccine may some great promise- "-Epimmune Inc., a majority-owned subsidiary of Cytel Corp. (Nasdaq:CYTL - news), today announced presentations by its scientists and collaborators of initial data suggesting that epitope-based vaccines hold promise for the control of HIV infection. Data from two HIV related model studies were presented at the ''Conference on HIV Vaccine Development'' in Keystone, Colo. ''These initial results provide further support for our continued pursuit of development of an epitope-based HIV vaccine,'' said Robert W. Chesnut, Ph.D., executive vice president, Research and Development of Epimmune. ''In one study involving macaque monkeys, a significant cytotoxic T-cell (CTL) response was induced in all vaccinated animals. The other study, conducted in transgenic mice, demonstrated the ability of our EpiGene™ construct to simultaneously induce potent responses to multiple CTL epitopes.'' biz.yahoo.com On the chance that the market begins to look for other HIV vaccine companies HIV on the Amex- formerly Cel-Sci may be seized upon. HIV reported yesterday that its own vaccine may also be on the right road toward success- "New Findings Support CEL-SCI's Aids Vaccine Approach Jan. 13 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV; Berlin Stock Exchange: LSR) has received numerous inquiries regarding a recent report by Johns Hopkins University investigators describing new findings of a key part of the AIDS virus in India. Their report suggests that there may be problems in the development of an AIDS vaccine based on the outside (envelope) of the virus. These new results support the alternative AIDS vaccine approach being pursued by CEL-SCI which focuses on the core of the virus. The Johns Hopkins University findings indicate that subtype C is predominant in India, as it is in Southern Africa. In contrast, the predominant subtype in the U.S. and Western Europe is subtype B. The researchers reported that the sequence of the envelope of the AIDS virus differs significantly between subtypes C and B. The implication of this finding is that the envelope-based HIV vaccines being pursued by other AIDS vaccine companies would probably not be useful in India and Southern Africa. CEL-SCI's HGP-30W AIDS vaccine has been designed mainly for the developing world where the disease is exploding. This makes CEL-SCI's vaccine efforts unique because other AIDS vaccines target the B-clade, which is prevalent in the U.S. and Western Europe but not in the developing world. biz.yahoo.com HIV trading near 2- look for traders to look for other AIDS/HIV vaccines